Kerendia (finerenone tablets – Bayer) — Cigna

Heart Failure with left ventricular ejection fraction ≥ 40%

Preferred products

Patient age ≥ 18 years; AND
Patient has left ventricular ejection fraction ≥ 40%; AND
Patient meets ONE of the following (a or b): a) Patient has tried or is currently receiving ONE of the following sodium glucose co-transporter-2 (SGLT-2) inhibitors: Farxiga (dapagliflozin tablets, authorized generic) OR Inpefa (sotagliflozin tablets) OR Jardiance (empagliflozin tablets); OR b) According to the prescriber, the patient has a contraindication or has experienced significant intolerance to SGLT-2 inhibitor therapy; AND
At baseline (prior to initiation of Kerendia), patient meets BOTH of the following (a and b): a) Estimated glomerular filtration rate ≥ 25 mL/min/1.73 m2; AND b) Serum potassium level ≤ 5.0 mEq/L

Patient is currently receiving Kerendia; AND
Patient age ≥ 18 years; AND
Patient has left ventricular ejection fraction ≥ 40%; AND
Patient meets ONE of the following (a or b): a) Patient has tried or is currently receiving ONE of the following sodium glucose co-transporter-2 (SGLT-2) inhibitors: Farxiga (dapagliflozin tablets, authorized generic) OR Inpefa (sotagliflozin tablets) OR Jardiance (empagliflozin tablets); OR b) According to the prescriber, the patient has a contraindication or has experienced significant intolerance to SGLT-2 inhibitor therapy